Clik here to view.
Coumadin®: Discontinuation of Sale
Dr. Stephan Moll and Beth Waldron write (last updated April 28, 2020): The company making Coumadin® (warfarin sodium) tablets, Bristol-Myers Squibb (BMS), announced that it will discontinue the sale...
View ArticleCoronavirus for patients: Plan your blood thinner medication refills
Beth Waldron, MA writes….For patients on life-saving therapies like blood thinners (anticoagulants) having several weeks supply of medication on hand during the coronavirus outbreak is important not...
View ArticleAntiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?
Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin...
View ArticleNew Oral Anticoagulant FDA Approved – Bevyxxa (Betrixaban)
Stephan Moll, MD writes… On June 23, 2017, the FDA approved a 5th new oral anticoagulant for clinical use, Bevyxxa® (= Betrixaban). It is approved to prevent DVT and PE in patients who are...
View ArticleAntidotes for the New Oral Anticoagulants: Update
Stephan Moll, MD writes… No reversal agent (antidote, neutralizing drug) is presently clinically available if (a) major bleeding occurs or (b) urgent reversal for emergent surgery is needed in patients...
View ArticleNew Oral Anticoagulants for DVT and PE: Update on FDA Applications
Stephan Moll, MD writes… 1. Pradaxa (Dabigatran) Today, August 28th, 2013, it was announced that the FDA is reviewing the application by Boehringer-Ingelheim to get Pradaxa (dabigatran) approved for...
View ArticleInternational Coagulation Meeting (ISTH 2013): Highlights
Stephan Moll, MD writes… A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; www.isth.org), took place in Amsterdam,...
View Article
